Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
4 hedge funds and large institutions have $5.12K invested in Protagenic Therapeutics Warrant in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
1.99% more ownership
Funds ownership: 4.3% → 6.29% (+2%)
0% more funds holding
Funds holding: 4 → 4 (0)
24% less capital invested
Capital invested by funds: $6.76K → $5.12K (-$1.64K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.98K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$53 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $2.56K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2.24K | +$2.98K | +62,218 | +245% |
|
|
TSS
3
Two Sigma Securities
New York
| $316 | +$53 | +1,110 | +10% |
|
4
Bank of America
Charlotte,
North Carolina
| $2 | – | – | – |
|
PTIXW Hedge Fund Activity: Q3 2025 in Review
4 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q3 2025, worth a combined $5.12K — down 24% from $6.76K a quarter earlier.
Fund positioning in PTIXW was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $2.98K.
- 4 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $5.12K of Protagenic Therapeutics Warrant stock for Q3 2025, down 24% quarter-over-quarter.
- 0 funds opened new Protagenic Therapeutics Warrant positions in Q3 2025 and 0 closed out.
- The largest Protagenic Therapeutics Warrant buyer in Q3 2025 was Susquehanna International Group, an estimated $2.98K added.
Based on aggregated 13F filings for Q3 2025.